Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 1/5 criteria met. Data as of 01/11/2026.
- ✅ Price trend passed
- ⚠️ Mixed growth
- ❌ Debt failed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): the price has been multiplied by at least 1.5.
Price change 2018 → 2019: 34.97%
Price change 2019 → 2020: 63.56%
Price change 2020 → 2021: 50.80%
Price change 2021 → 2022: -42.17%
Price change 2022 → 2023: 8.49%
Price change 2023 → 2024: -21.91%
Price change 2024 → 2025: 8.06%
Price change 2025 → 2026: 74.22%
Price change 2026 (year to date): 71.69%
Financial growth
Revenue CAGR (8 years): 8.52%
Earnings CAGR (8 years): N/A
Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.
Debt
Debt-to-equity ratio: 0.97
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 35.17
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 7.60% from the high over 6 months.
Insufficient correction (< 10.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="CRL" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Charles River Laboratories International, Inc. | 34.1 | 0.97 | +8.8 % | 🔒 |
| Ipsen S.A. | 25.6 | 0.20 | +7.9 % | – |
| Tempus AI, Inc. | – | 2.70 | +65.4 % | – |
| bioMérieux S.A. | 23.5 | 0.11 | +7.6 % | ★ 4/5 |
| BioNTech SE | – | 0.01 | +60.8 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Charles River Laboratories International, Inc. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 2.9 bn | 364 m | 12.5 % | n/a |
| 2021 | 3.5 bn | 391 m | 11.0 % | +21.1 % |
| 2022 | 4.0 bn | 486 m | 12.2 % | +12.3 % |
| 2023 | 4.1 bn | 475 m | 11.5 % | +3.9 % |
| 2024 | 4.0 bn | 10.3 m | 0.2 % | -1.9 % |
| 2025 | 4.0 bn | -144 m | -3.6 % | -0.9 % |
Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Charles River Laboratories International, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 246 m | 234 m | 277 m | 195 m | 214 m |
| Total Debt | 3.2 bn | 3.1 bn | 3.1 bn | 2.7 bn | 3.1 bn |
| Net Debt | 3.0 bn | 2.9 bn | 2.8 bn | 2.5 bn | 2.9 bn |
| Equity | 2.5 bn | 3.0 bn | 3.6 bn | 3.5 bn | 3.2 bn |
| Total assets | 7.0 bn | 7.6 bn | 8.2 bn | 7.5 bn | 7.1 bn |
| Operating cash flow | 761 m | 620 m | 684 m | 735 m | 738 m |
| Investments (capex) | 229 m | 325 m | 319 m | 233 m | 219 m |
| Free cash-flow | 532 m | 295 m | 365 m | 502 m | 518 m |
| Share buybacks | 40.7 m | 38.7 m | 24.2 m | 119 m | 361 m |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.
Valuation and competitors
Charles River Laboratories International, Inc. compared with its sector on the same exchange and with its main competitors.
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.
Analyst consensus and forecasts
What the financial analysts covering Charles River Laboratories International, Inc. publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Analysts' average target 313.67 USD, DCF value 84.38 USD, share price 337.52 USD.
Average target over the last 3 months: 333.83 USD (12 targets).
Analyst forecasts
| Fiscal year | Revenue | Net income | Expected EPS (range) | P/E on this EPS | Analysts |
|---|---|---|---|---|---|
| 2026 | 3.9 bn | 563 m | 11.38 (11.20 / 11.51) | 29.7 | 10 |
| 2027 | 4.0 bn | 619 m | 12.80 (12.10 / 13.06) | 26.4 | 10 |
| 2028 | 4.2 bn | 697 m | 14.33 (10.17 / 17.84) | 23.6 | 6 |
Amounts in USD, the reporting currency.
Track record against expectations: reported EPS above consensus 12 times over the last 12 releases.
Rating changes (12 months)
| Date | Firm | Before | After |
|---|---|---|---|
| 05/11/2026 | UBS | Buy | Buy |
| 05/11/2026 | RBC Capital | Outperform | Outperform |
| 05/11/2026 | Barclays | Overweight | Overweight |
| 05/11/2026 | Evercore ISI Group | Outperform | Outperform |
| 13/10/2026 | Morgan Stanley | Overweight | Overweight |
Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Charles River Laboratories International, Inc.
Indices: S&P 500 (since 14/05/2021).
Large funds tracked
| Fund | Shares | Value (USD) | Weight in the fund | Change | Quarter |
|---|---|---|---|---|---|
| Vanguard Group | 5.9 m | 1.2 bn | 0.0 % | +0.8 % | 2025Q4 |
| Fidelity | 4.2 m | 962 m | 0.0 % | +22.7 % | 2026Q2 |
| BlackRock | 3.8 m | 861 m | 0.0 % | -1.6 % | 2026Q2 |
| State Street | 3.7 m | 846 m | 0.0 % | +99.0 % | 2026Q2 |
| Invesco | 3.0 m | 677 m | 0.1 % | +24.5 % | 2026Q2 |
| Citadel Advisors | 2.4 m | 541 m | 0.2 % | +96.9 % | 2026Q2 |
| Harris Associates | 2.2 m | 508 m | 0.7 % | +4.1 % | 2026Q2 |
| Ariel Investments | 1.5 m | 342 m | 3.4 % | +4.3 % | 2026Q2 |
Latest insider transactions
| Date | Person | Side | Amount |
|---|---|---|---|
| 22/10/2026 | Foster James C | sale | 8.4 m USD |
| 21/10/2026 | Parisotto Shannon M | sale | 742,548 USD |
| 05/10/2026 | Parisotto Shannon M | sale | 302,580 USD |
| 30/09/2026 | Coleman Glenn | purchase | 2,974 USD |
| 25/08/2026 | Foster James C | sale | 10.1 m USD |
| 19/08/2026 | Parisotto Shannon M | sale | 599,711 USD |
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 16/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Charles River Laboratories International, Inc.
What is the Charles River Laboratories International, Inc. share price?
Latest recorded price: 337.97 USD on 13/11/2026, for a market cap of 16.2 bn USD.
What is the revenue of Charles River Laboratories International, Inc.?
4.0 bn USD for fiscal year 2025, with net income of -144 m USD (net margin -3.6 %).
When does Charles River Laboratories International, Inc. report its next earnings?
The next release is expected on 17/02/2027. EPS expected by analysts: 3.32.
What do analysts say about Charles River Laboratories International, Inc.?
Out of 37 analysts: 28 buy or strong buy, 9 hold, 0 sell or strong sell. Average price target: 313.67 USD, i.e. -7.1 % from the share price.
What is the P/E ratio of Charles River Laboratories International, Inc.?
Trailing 12-month P/E of 34.1, against 27.7 for the sector median on the same exchange (10-year median: 22.3).
Is Charles River Laboratories International, Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US1598641074).
How many employees does Charles River Laboratories International, Inc. have?
18,700 full-time employees according to the latest published profile.
Who runs Charles River Laboratories International, Inc.?
James C. Foster is the company's chief executive.
Which large funds own Charles River Laboratories International, Inc.?
As of 2026Q2, among the large funds tracked: Vanguard Group, Fidelity, BlackRock, State Street, Invesco.